Cargando…
Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
Stanozolol is a 17α-alkylated synthetic anabolic steroid used illegally by bodybuilders. We present a 19-year-old man who was taking 50 mg of stanozolol intramuscularly, every other day for 2 months, to improve muscle mass. On admission, his bilirubin concentration was 44.34 mg/dl. The serum levels...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421162/ https://www.ncbi.nlm.nih.gov/pubmed/28856252 http://dx.doi.org/10.5114/ceh.2015.51376 |
_version_ | 1783234546863439872 |
---|---|
author | Stępień, Piotr M. Reczko, Katarzyna Wieczorek, Anna Zarębska-Michaluk, Dorota Pabjan, Paweł Król, Teodora Kryczka, Wiesław |
author_facet | Stępień, Piotr M. Reczko, Katarzyna Wieczorek, Anna Zarębska-Michaluk, Dorota Pabjan, Paweł Król, Teodora Kryczka, Wiesław |
author_sort | Stępień, Piotr M. |
collection | PubMed |
description | Stanozolol is a 17α-alkylated synthetic anabolic steroid used illegally by bodybuilders. We present a 19-year-old man who was taking 50 mg of stanozolol intramuscularly, every other day for 2 months, to improve muscle mass. On admission, his bilirubin concentration was 44.34 mg/dl. The serum levels of liver enzymes were normal, with only alanine aminotransferase being slightly elevated. Liver biopsy revealed toxic hepatitis of minor grade with periportal fibrosis and intrahepatic cholestasis. Medical treatment of the patient was conservative. Despite the therapy the patient’s general condition deteriorated – bilirubin level increased to 56.64 mg/dl, and INR rose to 1.7. Then we decided to administer low doses of hydrocortisone. As a result of the treatment, bilirubin concentration was 14.61 mg/dl after 2 weeks. Finally all hepatic enzymes returned to normal values 5 months after stanozolol was discontinued. This treatment appears to be safe and leads to a more rapid reduction of bilirubin. |
format | Online Article Text |
id | pubmed-5421162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-54211622017-08-30 Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature Stępień, Piotr M. Reczko, Katarzyna Wieczorek, Anna Zarębska-Michaluk, Dorota Pabjan, Paweł Król, Teodora Kryczka, Wiesław Clin Exp Hepatol Case Report Stanozolol is a 17α-alkylated synthetic anabolic steroid used illegally by bodybuilders. We present a 19-year-old man who was taking 50 mg of stanozolol intramuscularly, every other day for 2 months, to improve muscle mass. On admission, his bilirubin concentration was 44.34 mg/dl. The serum levels of liver enzymes were normal, with only alanine aminotransferase being slightly elevated. Liver biopsy revealed toxic hepatitis of minor grade with periportal fibrosis and intrahepatic cholestasis. Medical treatment of the patient was conservative. Despite the therapy the patient’s general condition deteriorated – bilirubin level increased to 56.64 mg/dl, and INR rose to 1.7. Then we decided to administer low doses of hydrocortisone. As a result of the treatment, bilirubin concentration was 14.61 mg/dl after 2 weeks. Finally all hepatic enzymes returned to normal values 5 months after stanozolol was discontinued. This treatment appears to be safe and leads to a more rapid reduction of bilirubin. Termedia Publishing House 2015-04-30 2015-05 /pmc/articles/PMC5421162/ /pubmed/28856252 http://dx.doi.org/10.5114/ceh.2015.51376 Text en Copyright: © 2015 Clinical and Experimental Hepatology http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Case Report Stępień, Piotr M. Reczko, Katarzyna Wieczorek, Anna Zarębska-Michaluk, Dorota Pabjan, Paweł Król, Teodora Kryczka, Wiesław Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature |
title | Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature |
title_full | Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature |
title_fullStr | Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature |
title_full_unstemmed | Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature |
title_short | Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature |
title_sort | severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421162/ https://www.ncbi.nlm.nih.gov/pubmed/28856252 http://dx.doi.org/10.5114/ceh.2015.51376 |
work_keys_str_mv | AT stepienpiotrm severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature AT reczkokatarzyna severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature AT wieczorekanna severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature AT zarebskamichalukdorota severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature AT pabjanpaweł severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature AT krolteodora severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature AT kryczkawiesław severeintrahepaticcholestasisandliverfailureafterstanozololusagecasereportandreviewoftheliterature |